SG10202100168XA - Novel processes for preparation of soluble guanylate cyclase stimulators - Google Patents
Novel processes for preparation of soluble guanylate cyclase stimulatorsInfo
- Publication number
- SG10202100168XA SG10202100168XA SG10202100168XA SG10202100168XA SG10202100168XA SG 10202100168X A SG10202100168X A SG 10202100168XA SG 10202100168X A SG10202100168X A SG 10202100168XA SG 10202100168X A SG10202100168X A SG 10202100168XA SG 10202100168X A SG10202100168X A SG 10202100168XA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- guanylate cyclase
- soluble guanylate
- novel processes
- cyclase stimulators
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359430P | 2016-07-07 | 2016-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202100168XA true SG10202100168XA (en) | 2021-02-25 |
Family
ID=59351140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900125PA SG11201900125PA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
| SG10202100168XA SG10202100168XA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900125PA SG11201900125PA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11834444B2 (en) |
| EP (1) | EP3481821B1 (en) |
| JP (1) | JP7054395B2 (en) |
| KR (1) | KR102513357B1 (en) |
| CN (1) | CN109563086B (en) |
| AU (1) | AU2017292811B2 (en) |
| BR (1) | BR112019000292A2 (en) |
| CA (1) | CA3029376A1 (en) |
| CL (1) | CL2019000017A1 (en) |
| EA (1) | EA201990236A1 (en) |
| ES (1) | ES2962829T3 (en) |
| IL (1) | IL263994B (en) |
| JO (1) | JOP20180126A1 (en) |
| MA (1) | MA45593A (en) |
| MX (1) | MX382762B (en) |
| SG (2) | SG11201900125PA (en) |
| WO (1) | WO2018009602A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017291827B2 (en) | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| WO2018009602A2 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| TWI821237B (en) | 2018-01-10 | 2023-11-11 | 美商賽克瑞恩醫療公司 | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101955439A (en) * | 2009-07-14 | 2011-01-26 | 华东理工大学 | Method for resolving alpha-substituted-2-amino acetamide |
| US8748442B2 (en) | 2010-06-30 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| EP2663561B1 (en) * | 2011-01-13 | 2016-03-16 | Novartis AG | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| EP3112363A1 (en) | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension |
| JP2016517432A (en) * | 2013-03-15 | 2016-06-16 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC stimulant |
| JP6624616B2 (en) * | 2014-09-17 | 2019-12-25 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC stimulant |
| WO2017095697A1 (en) | 2015-11-30 | 2017-06-08 | Ironwood Pharmaceuticals, Inc. | Solid dispersions comprising a sgc stimulator |
| JP2019524710A (en) | 2016-07-07 | 2019-09-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Solid form of SGC stimulant |
| AU2017291827B2 (en) * | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| WO2018009602A2 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
-
2017
- 2017-07-06 WO PCT/US2017/040817 patent/WO2018009602A2/en not_active Ceased
- 2017-07-06 ES ES17740238T patent/ES2962829T3/en active Active
- 2017-07-06 JP JP2019500469A patent/JP7054395B2/en active Active
- 2017-07-06 CN CN201780048199.7A patent/CN109563086B/en active Active
- 2017-07-06 MA MA045593A patent/MA45593A/en unknown
- 2017-07-06 KR KR1020197003461A patent/KR102513357B1/en active Active
- 2017-07-06 SG SG11201900125PA patent/SG11201900125PA/en unknown
- 2017-07-06 EA EA201990236A patent/EA201990236A1/en unknown
- 2017-07-06 US US16/315,221 patent/US11834444B2/en active Active
- 2017-07-06 BR BR112019000292-8A patent/BR112019000292A2/en not_active Application Discontinuation
- 2017-07-06 MX MX2019000138A patent/MX382762B/en unknown
- 2017-07-06 EP EP17740238.5A patent/EP3481821B1/en active Active
- 2017-07-06 SG SG10202100168XA patent/SG10202100168XA/en unknown
- 2017-07-06 CA CA3029376A patent/CA3029376A1/en active Pending
- 2017-07-06 AU AU2017292811A patent/AU2017292811B2/en not_active Ceased
-
2018
- 2018-12-24 JO JOP/2018/0126A patent/JOP20180126A1/en unknown
- 2018-12-27 IL IL263994A patent/IL263994B/en unknown
-
2019
- 2019-01-04 CL CL2019000017A patent/CL2019000017A1/en unknown
-
2023
- 2023-10-30 US US18/385,025 patent/US12247025B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2962829T3 (en) | 2024-03-21 |
| SG11201900125PA (en) | 2019-02-27 |
| US11834444B2 (en) | 2023-12-05 |
| EP3481821B1 (en) | 2023-09-06 |
| MX382762B (en) | 2025-03-13 |
| JOP20180126A1 (en) | 2019-01-30 |
| CN109563086A (en) | 2019-04-02 |
| KR102513357B1 (en) | 2023-03-24 |
| US12247025B2 (en) | 2025-03-11 |
| EP3481821A2 (en) | 2019-05-15 |
| EP3481821C0 (en) | 2023-09-06 |
| IL263994A (en) | 2019-01-31 |
| WO2018009602A2 (en) | 2018-01-11 |
| US20210284632A1 (en) | 2021-09-16 |
| AU2017292811B2 (en) | 2021-10-21 |
| KR20190025987A (en) | 2019-03-12 |
| CA3029376A1 (en) | 2018-01-11 |
| IL263994B (en) | 2021-10-31 |
| EA201990236A1 (en) | 2019-08-30 |
| BR112019000292A2 (en) | 2019-04-16 |
| MX2019000138A (en) | 2019-06-10 |
| WO2018009602A3 (en) | 2018-03-15 |
| US20240199595A1 (en) | 2024-06-20 |
| JP2019524712A (en) | 2019-09-05 |
| AU2017292811A1 (en) | 2019-02-07 |
| CL2019000017A1 (en) | 2019-05-03 |
| CN109563086B (en) | 2023-05-23 |
| JP7054395B2 (en) | 2022-04-13 |
| MA45593A (en) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3433285T1 (en) | An improved process for the preparation of sugammadex | |
| ZA201708417B (en) | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine | |
| IL254894A0 (en) | Process for the preparation of dicycloplatin | |
| IL263995A (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
| IL260465B (en) | Process for the preparation of an antibody-rifamycin conjugate | |
| IL260011A (en) | Water-soluble derivatives of 3,5-diphenyl-diazole compounds | |
| IL261986B (en) | An improved process for the preparation of butorphanol tartrate | |
| IL275748A (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| SG10202100168XA (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
| PL3583094T3 (en) | Process for the preparation of 2-cyanoimidazole compounds | |
| PL3510111T3 (en) | Methods for preparing powder coating compositions | |
| IL276852A (en) | Process for preparing soluble guanylate cyclase stimulators | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| PL3313194T3 (en) | Process for the preparation of aroma-retaining soluble coffee | |
| PL3228619T3 (en) | Process for the preparation of apixaban | |
| HUE049682T2 (en) | New processes for the preparation of vemurafenib | |
| HK40103206A (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
| PT3310711T (en) | Process for the preparation of sodiuim cyanide | |
| IL267198B (en) | Process for the preparation of powder compositions | |
| PL3478726T3 (en) | Bulkpolymerisation process for the preparation of polydienes | |
| LT3393246T (en) | Process for the preparation of a quelating agent | |
| TWI562978B (en) | Method for preparation of 1,4-cyclohexanedialkanol | |
| HUE052641T2 (en) | Process of preparing low abuk oxymorphone hydrochloride | |
| HUP1500034A1 (en) | Process for the preparation of vortioxetine salts |